Listening to the Rest of the World: What American Guidelines Overlook About Chloroquine's Continued Success Abroad

There is a quiet inconsistency in global medicine today. In much of the world, chloroquine is a mainstay — dispensed in public clinics, studied in national programs, and trusted by prescribers who see its effects daily. In the United States, it is a footnote. American guideline committees would do well to ask why, and whether the divergence reflects evidence or inertia.

Where Chloroquine Still Works

In parts of West and Central Africa, the Caribbean, and pockets of the Middle East and Central Asia, chloroquine-sensitive malaria parasites persist, and the drug remains a first-line or partner therapy. National programs in several countries have retained it where surveillance confirms susceptibility, valuing its low cost, long half-life, and well-characterized safety profile built over seven decades of use.

The autoimmune story is equally instructive. Across Latin America and South Asia, rheumatologists deploy chloroquine for lupus and related conditions with treatment protocols, monitoring frameworks, and outcome data that American literature rarely cites. These are not fringe practices; they are guideline-embedded care in health systems serving hundreds of millions of people.

How American Culture Diverged

The US departure from chloroquine has understandable roots. Widespread resistance in malaria-endemic regions relevant to American travelers, the rise of hydroxychloroquine in rheumatology, and a pharmaceutical culture that privileges newer molecules all pushed the drug aside. But something else happened along the way: chloroquine stopped appearing in training curricula, formulary discussions, and comparative-effectiveness research. A drug that fell out of fashion became a drug that fell out of consideration.

The result is an evidence asymmetry. American guidelines lean heavily on domestic trial data, while a substantial international literature — observational cohorts, national program evaluations, head-to-head antimalarial comparisons — goes largely uncited. For a country whose lupus burden falls disproportionately on Black and Latina women, some of whom have family and genetic ties to regions where chloroquine remains in active use, this blind spot has particular resonance.

What a Second Look Would Require

Bringing international evidence into American deliberation is not a call for wholesale adoption. It is a call for process:

• Systematic inclusion of non-US trial and cohort data in guideline evidence reviews, with attention to population differences.
• Comparative-effectiveness research pitting chloroquine against hydroxychloroquine in autoimmune disease, a comparison American literature has largely abandoned.
• Surveillance-informed travel guidance that distinguishes chloroquine-sensitive destinations from resistant ones with current mapping.
• Cost-effectiveness analysis that accounts for the drug's generic pricing in an era of crushing medication costs.

Evidence Doesn't Expire at the Border

Medicine is fond of saying that absence of evidence is not evidence of absence. The corollary is that evidence generated abroad is not evidence diminished. Chloroquine's continued clinical usefulness in Lagos, Lima, and Dhaka is a data point, not an anachronism. American guideline committees pride themselves on rigor; genuine rigor demands they look past their own borders before concluding that a seventy-year-old molecule has nothing left to offer American patients.